Literature DB >> 28176918

Dynamics of pulse wave velocity and vascular augmentation index in association with endothelial progenitor cells in SLE.

Peter Korsten1, Daniel Patschan1, Elvira Henze1, Timothy B Niewold2, Gerhard Anton Müller1, Susann Patschan1.   

Abstract

Patients with SLE display a significantly higher cardiovascular risk (CVR). Pulse wave velocity (PWV) has meanwhile been established as a reliable parameter of end-organ damage. Endothelial progenitor cells (EPCs) are critically involved in vascular repair under both physiological and pathological conditions. The aim of the study was to analyse PWV and the Vascular Augmentation Index (VAI) and EPC numbers/regeneration in a well-defined German SLE cohort. Thirty patients were included. Only two individuals displayed a PWV of above 10 m/s. There was no correlation between PWV percentiles and disease activity as reflected by the SLE Disease Activity Index. Neither EPC colonies nor percentages of circulating EPCs (CD133+/KDR+) correlated with PWV/VAI in a positive or negative manner. Thus, it can be questioned whether pulse wave analysis and/or EPC proliferation and circulating cell numbers are truly useful for CVR assessment in SLE.

Entities:  

Keywords:  cardiovascular risk; endothelial progenitor cells; pulse wave velocity

Year:  2016        PMID: 28176918      PMCID: PMC5237712          DOI: 10.1136/lupus-2016-000185

Source DB:  PubMed          Journal:  Lupus Sci Med        ISSN: 2053-8790


Patients with SLE have a prevalence of cardiovascular disease up to 50 times higher than healthy individuals.1 Recently, we were able to show that regeneration of endothelial progenitor cells (EPCs) may be impaired in SLE.2 Aortic pulse wave velocity (PWV) measurement and the central Vascular Augmentation Index (VAI) serve as surrogate markers for arterial stiffness. They represent independent predictors of cardiovascular structural damage and correlate with clinical outcomes.3 4 The aim of this study was to correlate parameters of vascular stiffness with EPC regeneration/circulating EPCs in a well-defined German SLE cohort. The patients were consecutively recruited from the Clinic of Nephrology and Rheumatology of the University Hospital of Göttingen. Prevalences of the following comorbidities were arterial hypertension, 61%; smoking, 26%; use of steroids, 82% and statin therapy, 13% (table 1).
Table 1

Baseline characteristics of patients

Age (years)DOD (years)SLE DAICFU-ECs (n)CD133+/Flk+ (%)PWV (m/s)VAI
Mean43.5811.775.5819.190.756.4323.17
SD15.348.884.3419.570.481.7413.36

CFU-ECs, colony-forming unit-endothelial cells; DAI, disease activity index; DOD, duration of diseases; PWV, pulse wave velocity; VAI, vascular augmentation index.

Baseline characteristics of patients CFU-ECs, colony-forming unit-endothelial cells; DAI, disease activity index; DOD, duration of diseases; PWV, pulse wave velocity; VAI, vascular augmentation index. Analysis of PWV and VAI were successfully performed in 23 of 30 patients. All patients signed written consent to participate. The mean PWV was 6.4±1.7 m/s in all patients. Only two individuals displayed a PWV of above 10 m/s (10.4 and 11.3 m/s). PWV positively correlated with age (p=0.024). There was no correlation between PWV percentiles and disease activity as reflected by the SLE Disease Activity Index. The latter did also not correlate with the VAI percentiles, but anti-double stranded DNA levels correlated with the augmentation index in a negative manner (correlation coefficient −0.46, p=0.029). Neither EPC colonies nor percentages of circulating EPCs (CD133+/KDR+) correlated with PWV/VAI in a positive or negative manner (figure 1).
Figure 1

Correlation analysis between colony-forming unit-endothelial cells (CFU-ECs)/CD133+/KDR+ cells and pulse wave velocity (PWV)/vascular augmentation index (VAI). Neither cell regeneration, as reflected by the number of colonies growing in culture, nor percentages of circulating CD133+/KDR+ cells correlated with PWV or VAI in a positive or negative manner.

Correlation analysis between colony-forming unit-endothelial cells (CFU-ECs)/CD133+/KDR+ cells and pulse wave velocity (PWV)/vascular augmentation index (VAI). Neither cell regeneration, as reflected by the number of colonies growing in culture, nor percentages of circulating CD133+/KDR+ cells correlated with PWV or VAI in a positive or negative manner. The most intriguing result of the current investigation was related to the absolute PWV values in patients with SLE with only two individuals displaying a PWV of above 10 m/s. A PWV of above 10 m/s has meanwhile been accepted as marker of cardiovascular end-organ damage.5 Castejon et al6 reported a mean PWV in SLE of 7.8±2.2 m/s with lower percentages of circulating EPCs in those patients displaying pathological PWV values. Nevertheless, the absolute range of PWV values in this particular category was not mentioned in the study. Comparable data have been reported by Valero-Gonzalez but once again, the absolute range of values is missing.7 A very early investigation was published in 2001, evaluating PWV in female patients with SLE with a mean PWV of 6.1±1.7 m/s.8 In a newer study, participants were subdivided into two subgroups (brachial-ankle PWV (baPWV) <14 vs >14 m/s). Nevertheless, the mean baPWV in all individuals was 15±0.38 m/s.9 Finally, Sacre et al10 reported a mean PWV of 6.3±0.8 m/s. Therefore, our observation has two implications: the absolute PWV may significantly vary in SLE, most likely depending on the subjects investigated and the method used for PWV analysis. In addition, EPC colony formation/circulating EPCs may not reliably correlate with parameters of vascular stiffness. Thus, it can be questioned whether pulse wave analysis and/or EPC proliferation and circulating cell numbers are truly useful for cardiovascular risk assessment in SLE. Finally, it needs however to be mentioned that the current study was performed in an uncontrolled manner which may account for some limitations.
  10 in total

Review 1.  The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society.

Authors:  Charalambos Vlachopoulos; Panagiotis Xaplanteris; Victor Aboyans; Marianne Brodmann; Renata Cífková; Francesco Cosentino; Marco De Carlo; Augusto Gallino; Ulf Landmesser; Stéphane Laurent; John Lekakis; Dimitri P Mikhailidis; Katerina K Naka; Athanasios D Protogerou; Damiano Rizzoni; Arno Schmidt-Trucksäss; Luc Van Bortel; Thomas Weber; Akira Yamashina; Reuven Zimlichman; Pierre Boutouyrie; John Cockcroft; Michael O'Rourke; Jeong Bae Park; Giuseppe Schillaci; Henrik Sillesen; Raymond R Townsend
Journal:  Atherosclerosis       Date:  2015-05-16       Impact factor: 5.162

2.  Endothelial progenitor cells in systemic lupus erythematosus.

Authors:  Susann Patschan; Daniel Patschan; Marta Potulski; Elvira Henze; Jürgen Scholze; Gerhard Anton Müller
Journal:  J Nephrol       Date:  2013-07-11       Impact factor: 3.902

3.  Increased arterial stiffness is independently associated with metabolic syndrome and damage index in systemic lupus erythematosus patients.

Authors:  S Valero-Gonzalez; R Castejon; C Jimenez-Ortiz; S Rosado; P Tutor-Ureta; J-A Vargas; M Yebra-Bango
Journal:  Scand J Rheumatol       Date:  2013-09-19       Impact factor: 3.641

4.  Association of brachial-ankle pulse wave velocity with cardiovascular risk factors in systemic lupus erythematosus.

Authors:  T K Tso; W N Huang; H Y Huang; C K Chang
Journal:  Lupus       Date:  2005       Impact factor: 2.911

5.  Metabolic syndrome is associated with decreased circulating endothelial progenitor cells and increased arterial stiffness in systemic lupus erythematosus.

Authors:  R Castejon; C Jimenez-Ortiz; S Rosado; P Tutor-Ureta; S Mellor-Pita; M Yebra-Bango
Journal:  Lupus       Date:  2015-09-09       Impact factor: 2.911

Review 6.  Arterial elastance and wave reflection augmentation of systolic blood pressure: deleterious effects and implications for therapy.

Authors:  W W Nichols; D G Edwards
Journal:  J Cardiovasc Pharmacol Ther       Date:  2001-01       Impact factor: 2.457

7.  Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study.

Authors:  A Elisabeth Hak; Elizabeth W Karlson; Diane Feskanich; Meir J Stampfer; Karen H Costenbader
Journal:  Arthritis Rheum       Date:  2009-10-15

8.  Vascular stiffness in women with systemic lupus erythematosus.

Authors:  F Selzer; K Sutton-Tyrrell; S Fitzgerald; R Tracy; L Kuller; S Manzi
Journal:  Hypertension       Date:  2001-04       Impact factor: 10.190

9.  Arterial wave reflections and incident cardiovascular events and heart failure: MESA (Multiethnic Study of Atherosclerosis).

Authors:  Julio A Chirinos; Jan G Kips; David R Jacobs; Lyndia Brumback; Daniel A Duprez; Richard Kronmal; David A Bluemke; Raymond R Townsend; Sebastian Vermeersch; Patrick Segers
Journal:  J Am Coll Cardiol       Date:  2012-10-24       Impact factor: 24.094

10.  Increased arterial stiffness in systemic lupus erythematosus (SLE) patients at low risk for cardiovascular disease: a cross-sectional controlled study.

Authors:  Karim Sacre; Brigitte Escoubet; Blandine Pasquet; Marie-Paule Chauveheid; Maria-Christina Zennaro; Florence Tubach; Thomas Papo
Journal:  PLoS One       Date:  2014-04-10       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.